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ABSTRACT 
VERGENCE EYE MOVEMENT PARAMETERS FOR PRE/POST-OBVAT AND 
SHAM THERAPY ON BINOCULARLY NORMAL CONTROLS  
 
by 
Joel V. Rajah 
 
Vergence is the disjunctive movement of the eyes to maintain single binocular vision. 
Vergence eye movements are necessary to maintain the object of interest on the fovea of 
each eye as an individual looks from one object to another. Recent studies show that office 
based vergence/accommodative therapy (OBVAT) is an effective treatment for the 
binocular dysfunction known as convergence insufficiency. This study was performed to 
investigate the changes in oculomotor parameters parameter data for pre- and post-therapy 
subjects who are binocularly normal controls. A haploscope was used to collect eye 
movement data pre- and post-therapy. The analysis of the eye movements was done in 
MATLAB. Fifty binocularly normal controls participated in 12 hours of office-based 
therapy where half participated in OBVAT and the remaining half participated in office-
based placebo therapy (OBPT) therapy. The latency, time to peak velocity, peak velocity, 
response amplitude, final amplitude, and main sequence ratio were measured for 
participant’s responses to 4-degree and 6-degree ramps, 4- and 6-degree disappearing steps, 
6- and 10-degree stepramps, and 5- and 10-degree saccades. Peak velocity was 
significantly greater post OBVAT therapy compared to baseline, most of them having a 
p≤.001. Clinically meaning differences were not observed post OVPT compared to 
baseline. Results support that OBVAT significantly changes vergence dynamics and may 
be used for sports enhancement. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Objective 
This study will determine the effect of OBVAT vs OBPT (active vs sham therapy) on 
subjects with normal binocular vision. A haploscope will be used to capture eye 
movements during the assessment protocol which occurs before and after respective 
therapies are given. It is hypothesized that subjects participating in the active OBVAT 
therapeutic intervention will exhibit significant improvements in oculomotor 
parameters in comparison to the subjects who participated in sham therapy. 
1.2 Eye Physiology 
The eye is a complicated organ with many components required to allow normal vision 
to occur. There are some shortfalls that arise due to the way the components work 
together but are compensated for by eye movements. The conjunctiva is a thin layer in 
the front of the eye that prevents bacteria and foreign material from entering1. The 
sclera is the white part of the eye that surrounds the eye and gives it its shape (Fig 1.1). 
The cornea is at the front and center of the eye and helps focus light as it enters the eye 
(Fig 1.1)1. The iris controls the amount of light that enters the pupil, which allows light 
to reach the back of the eye (Fig 1.2). The lens and its controlling muscle ring, the 
ciliary body, finely focus light as it enters the eye, also helping the cornea focus light 
onto the retina (Fig 1.2) 1. The retina is the light detecting part of the eye and is made 
up of layers (Fig 1.3) 1. The neural layer contains nerve cells, some blood vessels, and 
cones and rods (photoreceptors). Signals travel from the photoreceptors via 
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interneurons then ganglion cells (the axons of which make the optic nerve) to the optic 
chasm then the lateral geniculate nucleus (LGN) and finally the visual cortex39. Cones 
are responsible for color vision while rods are used for low light vision. The optic disk 
is where the optic nerve exits the eye and has no photoreceptors, creating a “blind spot” 
in vision1. The fovea has a high concentration of photoreceptors and is responsible for 
high acuity vision1. Eye movements are used to project the images of interest to the 
fovea which has the highest acuity within the retina. These parts of the eye are vital in 
binocular vision, and the shortfalls of the physiology is counteracted by eye 
movements.  
 
Figure 1.1 This figure shows the location of the cornea (green) and sclera (blue) in 
the eye.  
 
Source [1] 
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Figure 1.2 This figure shows the location of the choroid (red), iris (purple) and ciliary 
body (yellow) in the eye. 
 
Source [1] 
 
Figure 1.3 This figure shows the optic disc and fovea.  
 
Source [1] 
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 Eye movements require muscles to rotate the eyes in certain directions. The six 
muscles that control eyeball position can be divided into two groups: two oblique 
(superior and inferior oblique muscles2) and four recti muscles (superior rectus, inferior 
rectus, medial rectus and lateral rectus muscles) (Fig 1.4) 2. The superior and inferior 
rectus are principally responsible for elevation and depression respectively. The medial 
rectus mainly adducts the eye, while the lateral rectus mainly abducts the eye2. The 
superior and inferior oblique muscles respectively medially and laterally rotate the eye. 
The muscles of import are the medial and lateral recti, being used in the rotation of the 
eyes to the left and right. Without these rotations, no vergence or version eye 
movements can occur.  
 
 
Figure 1.4 This illustrates the six muscles that control the movement of the eye and 
the muscle in control of the upper eyelid. 
 
Source [2] 
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1.3 Vergence System 
The vergence system is one of the ways the eyes’ physiological shortfalls are 
counteracted. Vergence is a disjunctive (both eyes move in opposition, inward or 
outward) eye movement, while saccadic eye movements are a version eye movement 
(they are conjunctive, meaning eyes move in parallel) 3-5. There are two types of 
vergence movements: convergence (eye rotate outward) and divergence (eyes rotate 
inward) 3-5. Convergence allows tracking a target located far away from a person to an 
object located close to a person while divergence tracks objects located near to those 
far. Vergence and version movements were both used in the assessment procedure.  
1.4 Control of Disparity Vergence 
Vergence has been described using two systems: a fast-fusional phasic system (FFPS) 
and a slow-fusional tonic system (SFTS)14 (shown in Figure 1.5).  The SFTS may also 
be called the phoria, or the resting eye level.  The phoria is typically measured when 
the eyes are dissociated. Phoria can be classified as esophoria, exophoria, hyperphoria, 
or cyclophoria3,24. Esophoria is a condition in which the eyes have a tendency to turn 
in, while in exophoria the eyes have a tendency to drift outward. Hyperphoria the eyes 
tend to drift up or downward and in cyclophoria the top of the eye rotates clockwise or 
counter clockwise. Heterophoria is the generic term used to describe all of these 
conditions in which the eyes have a tendency to drift from alignment when vergence is 
open-looped which can be done when the eyes are dissociated, such as with occlusion, 
or associated, such as with polarized lenses. The visual system adjusts for phoria 
alignment using fusional vergence. Version movements, when the eyes move in the 
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same direction as opposed to vergence movements in which the eye move in opposite 
directions, may have a connection to slow fusional vergence24 
The FFPS has been described by the Dual Mode Theory has having two parts, the 
fusion initiating component (FIC) and the fusion sustaining component (FSC) 14,28-31. 
The FIC is the preprogrammed component that allows the eyes to align near the target 
while the feedback component (FSC) moves the eyes the rest of the way to the 
target14,28-31. The FIC determines the velocity components (time to peak velocity, peak 
velocity, and response amplitude) of the movement while the FSC facilitates eye 
alignment reaching the final amplitude of the movement. This study will investigate 
the Dual Mode components of vergence. 
 
Figure 1.5 This is a figure of the Dual Mode Model. 
 
1.5 Convergence Insufficiency Treatment Trial 
The Convergence Insufficiency Treatment Trial (CITT) was a study designed to compare 
different vision therapeutic interventions as treatments for convergence insufficiency (CI) 
in children ranging from 9-17 years of age6. The randomized clinical trial had 221 children 
with symptomatic CI randomly assigned to office-based vergence/accommodative therapy 
with home reinforcement (OBVAT), office-based placebo therapy with home 
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reinforcement (OBPT), home-based computer vergence/accommodative therapy and 
pencil push-ups (HBCVAT+), or home-based pencil push-ups (HBPP) for 12 weeks. At 
the end of the study, it was shown that the group that underwent the OBVAT had a mean 
Convergence Insufficiency Symptom Survey (CISS) score statistically significantly 
(p<.001) lower than that of the OBPT, HBPP, and the HBCVAT+ groups6. The OBVAT 
group also saw a significant improvement in mean NPC and PFV at near compared to the 
other groups. A “successful outcome” was defined as a score of <16 on the CISS, a normal 
NPC (less than 6 cm), and normal PFV (greater than 15Δ and passing Sheard’s criterion), 
while an “improved outcome” was defined as a score of <16 or a 10 point decrease in the 
CI Symptom Survey score, and at least one of the following: normal NPC, an improvement 
in NPC of more than 4 cm, normal PFV or an increase in PFV of more than 10Δ6. 73% of 
the OBVAT group showed a successful or improved outcome, while 43%, 33%, and 35% 
of the HBPP, HBCVAT+, and OBPT saw a successful or improved outcome respectively. 
OBVAT and the other therapies can be assessed using objective parameters such as latency, 
time to peak velocity, peak velocity, response amplitude, final amplitude, and main 
sequence ratio18,22. The OBVAT and OBPT procedures were used in this study, with half 
of the subjects being randomly placed in one with the other half of the subjects being placed 
in the other. 
 
1.6 Prior Research of Vision Therapy in Binocularly Normal Controls  
Research has been conducted studying vision therapy on binocularly normal controls.  
Daum42 conducted a study with 35 young adults BNCs in which subjects were trained for 
10 minutes a day for 5 days. All subjects were initially assessed, with 23 being evaluated 
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(assessed again) after one week of training and 12 being evaluated 6 months after training 
was complete. Another study by Semmlow, Hung, and Ciuffreda43 utilizing two 
experienced subjects and one naïve subject studied the vergence response to ramp stimuli. 
A retrospective study was done by Ciuffreda et al.43 which found people with TBI present 
with oculomotor dysfunction. 90% of subjects saw improvement or remediations of visual 
symptoms after vision therapy. Yang, Bucci, and Kapoula44 found that latency was longer 
in adults than in children, and that convergence latency was longer than divergence latency 
studying 15 binocularly normal children and 15 binocularly normal adults. Talasan et al. 21 
performed a similar study to this present study, except instead of a sham cohort the study 
included a cohort who did not participate in therapy but had two assessment session 
separated by several weeks. This study expands on this previous work. 
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CHAPTER 2 
METHODOLOGY 
 
An assessment protocol was developed to quantitatively assess the results of the treatments. 
All subjects underwent the assessment before and after they participated in OBVAT (active 
therapy) or OBPT (sham therapy). A haploscope was used for the assessment protocol and 
clinical parameters as described by CITT were collected for all participants. Data were 
preprocessed, calibrated, classified, and analyzed in MATLAB. This section describes the 
experimental setup and protocol setups used in this study. 
 
2.1 Subject/Screening 
Binocularly normal subjects (N=50) were used in this study. They range from age 18-34 
years. There were 15 female and 35 male subjects. All subjects signed informed consent 
approved by the NJIT review Board in accordance to the Declaration of Helsinki. They 
were naïve as to which therapy they would be undergoing. 25 BNC (26 ± 8 years 19 M) 
were assigned using the consort to OBVAT and 25 (22 ± 4 years 16 M) were assigned to 
sham therapy using CONSORT agreement. 
 To be eligible for the study, subjects were required to have normal binocular vision 
defined as 20/20 (corrected if needed) acuity diagnosed by an optometrist, a near point of 
convergence of less than 6 cm, near phoria less than 4 prism diopters compared to far 
phoria, stereopsis less than 70 sec of arc, a normal positive fusional vergence (greater than 
15 prism diopters and passing Sheard’s criterion), and no history of neurological or eye 
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disease or dysfunction. These parameters were tested using, in order, the near point of 
convergence (NPC) test, Maddox rod test, and stereopsis tests. 
The NPC is the distance, in cm, along the midline that a person sees double vision 
when trying to focus on a target. The Maddox rod test measures a subject’s phoria level in 
prism diopters. To convert prism diopters to degrees, the equation degrees = tan-1(Δ/100) 
×180/π is used34. 
The Convergence Insufficiency Symptom Survey (CISS) was used to determine 
subject use in the study. The survey detects that a subject possibly has CI via the subject’s 
symptoms. In order to determine whether or not the subject has CI, they would need to get 
diagnosed by an optometrist. Scores below 21 indicate a binocularly normal subject. Scores 
above 21 indicate that the person is visually symptomatic. The survey is also used as an 
outcome measure in treatment of CI. 
The stereopsis test was used to determine whether the subject has normal depth 
perception. The active therapy BNC had a CISS of 7.37 ± 4.95, NPC of 3.82 ± 1.33, and 
PFV of 31.76 ± 8.83 before therapy (Table 2.1). The sham therapy BNC had a CISS of 
8.96 ± 5.56, NPC of 3.76 ± 1.15, and PFV of 30.92 ± 8.4 before therapy (Table 2.1).  The 
groups averaged out to be nearly identical in scores for CISS, NPC, and PFV. 
Table 2.1 Table of Subject Averages 
 Age Gender CISS NPC PFV 
OBVAT Subjects 26 ± 8 19M, 6F 7.37 3.82 31.76 
OBPT Subjects 22 ± 4 16M, 9F 8.96 3.76 30.92 
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2.2 Experimental Setup 
2.2.1 Instrumentation 
 
Figure 2.1 shows the assessment setup. This study utilizes the ISCAN RK-826PCI 
binocular tracking system (Burlington, MA) to record horizontal eye movements using the 
pupil as a natural anatomical marker. The device also records pupil diameter, vertical eye 
movements, and the movements of the reflection from the corneal surface. The eye 
movements are recorded using an infrared emitter and specialized infrared cameras. The 
emitters are used to bathe the eyes in light with a 950 nm wavelength and a power of 1.2 
mW/cm2. Using one camera per eye, the absence of infrared light from the pupil is used to 
locate the centroid of the pupil with the ISCAN software. The average accuracy of 0.3 
degrees over a ±20 degrees horizontal/vertical range is reported by the manufacturer.  
 
Figure 2.1 Haploscope experimental setup: presents vergence movement targets while 
the eye tracking instrumentation record the resulting eye movements.  
2.2.2 VisualEyes Software, Stimuli Presentation, and Data Collection 
 
VisualEyes is a custom LabVIEWTM (National Instruments, Austin, TX) program that 
controls the stimuli presentation and data collection from the experimental instrumentation. 
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The software separately presents visual stimuli to the left and right eye using two monitors, 
one for each eye, and partially reflective mirrors11. As shown in Figure 2.1, each monitor 
produces a stimulus which is transposed onto and reflected by the mirrors. The reflection 
simulates a symmetrical disparity vergence stimulus along the midline of the subject. In 
order to keep accommodation constant, the total distance that the stimulus (the focal length) 
travels is 40 cm for the entire experiment. This study was to only examine disparity 
vergence. This was achieved using a Gabor patch (Fig 2.2). The digitization of the eye 
movement data recorded from each eye from the ISCAN instrumentation is done by a 12-
bit digital acquisition (DAQ) card (National Instruments 604 E series, Austin, TX) with a 
sampling frequency of 500 Hz.  
 
Figure 2.2 This is a figure of a Gabor Patch. 
 
Source [38] 
2.3 Experimental Procedure 
2.3.1 Assessment Procedure 
An assessment procedure was required to determine whether changes to the vergence 
oculomotor system would occur. This assessment was given before and after the therapy 
procedure. The assessment and therapy procedures were different to reduce potential 
procedural learning. The 12 weeks in between the first and final assessment also reduced 
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the potential of procedural learning. Phoria level was not accounted for in the assessment 
and was not individualized for each subject. Four types of movements were presented with 
the using the stimuli presented in table: ramps, disappearing steps, step ramps, and 
saccades. These are shown in Figure 2.3. They are notated as the type of movement 
followed by the degree change (Table 2.2). 
  
Figure 2.3 There are different types of stimuli movements, shown above. Convergence 
(Left, top), Divergence (left, bottom), and Saccadic (right) movement are shown. 
Convergence and divergence show different stimuli to each eye (disjunctive) while 
saccades show the same stimuli (conjunctive). 0 represents the baseline degree in which 
the stimuli are initially placed while 2 denotes the stimuli’s final degree. B: Schematic 
representation of 4 deg symmetrical disparity step, disappearing step (with the stimulus 
disappearing after 100 milliseconds), and stepramp disconjugate stimuli. (6 deg disparity 
stimuli also studied but not shown) C: Schematic representation of 5 deg saccadic stimuli 
(10 deg stimuli also studied but not shown). 
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Table 2.2 Table of Movement Abbreviations  
Type of Movement Example Full Name of Example Degree of Movement 
Disparity Step Con48 Convergence 4 to 8 degrees 
Disappearing Step DSCon26 Convergence Disappearing 
Step 
2 to 6 degrees 
Stepramp FastCon212 Fast Convergence Stepramp 2 to 12 degrees 
Saccade L2M5 Left to Middle 5 degrees 
 
2.3.2 Therapy Procedure 
 
There was an OBPT and an OBVAT utilized. The OBPT consisted of changing techniques 
weekly. Necker Cube, HTS Placebo Accommodation and Vergence, Monocular Brock 
String, Visual Closure, Double Maddox rod, and more techniques were used. These 
techniques are normally designed to improve monocular inputs, eye focusing, ability to 
detect targets, visual response speed, eye teaming skills, and visual processing skills. These 
are not designed to be used for improving vergence or accommodation but are designed to 
give subjects the impression that they are receiving the appropriate therapy. The schedule 
is shown in Figure 2.4.  The OBVAT consisted of three phases, shown in Figure 2.5. Phase 
One consisted of gross convergence, positive fusional vergence, and monocular 
accommodative therapy. Phase two consisted of ramp fusional vergence and monocular 
accommodative therapy. Phase three consisted of jump fusional vergence and binocular 
accommodative facility. These phases included such techniques such as vectograms, Brock 
String, Barrell Card, Loose Lens Accommodative Rock, Letter Chart Accommodative 
Rock, Life Saver Cards, Eccentric Circles, HTS, and more. These techniques used in 
OBVAT are designed to improve both vergence and accommodation. 
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Figure 2.4 This is the schedule of the entirety of sham therapy.  
Source [36] 
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Figure 2.5 These are the OBVAT therapy phases. 
Source [37] 
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2.4 Data Analysis 
2.4.1 Data Processing 
MATLAB was used to import and analyze the eye movement data. The raw right eye 
positional data subtracted from the left eye positional data to compute the vergence 
movement. This required the assumption that the resolutions of both eyes were the same 
when the data were collected. Far vergence step response calibration consisted of a six-
point, monocular calibration. The 1°, 3°, and 5° monocular, corresponded to the 2°, 6°, 10° 
binocular vergence angle demand. Near vergence step response calibration consisted of a 
six-point, monocular calibration. The 4°, 5°, and 6° monocular, corresponded to 8°, 10°, 
12° binocular vergence angle demand. These calibrations were performed before and after 
completion of each experimental group. Other steps in the data analysis included the 
removal of outliers (2 standards deviations away from the mean), blink removal (easily 
identified by the large signal seen as the camera loses the eye image due to the closing of 
the eyelids), and the acquiring of the velocity trace of each movement. Any movements 
with a saccade in the transient were removed. 
2.4.2 Eye Movement Parameters Analyzed  
There were 6 aspects of the eye movement that were measured: the latency, time to peak 
velocity, peak velocity, response amplitude, final amplitude, and main sequence ratio. The 
main sequence ratio in this case is the ratio of the peak velocity and response amplitude. 
These were compared for the before and after therapy data, between the sham and placebo 
therapy, and between genders using a mixed ANOVA. Figure 2.6 shows a typical vergence 
eye movement, with all parameters that were measured labelled on the graph. The peak 
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velocity and time to peak velocity is measured using the velocity graph. Figure 2.7 shows 
the phase plot of response amplitude, which is how response amplitude was determined. 
 
Figure 2.6 In this figure, A represents a typical 4-degree convergence eye movement, and 
B represents the velocity graph of the movement. The latency, response amplitude, and 
final amplitude can be measured on A while B is used to measure the time to peak velocity 
and peak velocity. Main sequence ratio is the ratio between the peak velocity and response 
amplitude. 
 
Figure 2.7 In this figure, the phase plot of response amplitude is shown. The raw data of 
velocity to position is plotted, with is then filtered. The new curve is then used to find the 
response amplitude. 
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X = response amplitude 
O = target response amplitude 
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CHAPTER 3 
RESULTS 
3.1 Clinical Results 
Table 3.1 Table of Active Therapy Subject Information  
Subject Type Therapy Age/Gender CISS 
Before/After 
NPC 
Before/After 
PFV 
Before/After 
NIH021 BNC Active 22/M /15 4/4 35/45+ 
NIH022 BNC Active 19/M 15/11 4/5 40/50 
NIH058 BNC Active 18/M 4/10 7/5.5 18/40 
NIH059 BNC Active 18/F 5/4 6/5.5 20/40 
NIH063 BNC Active 24/M 13/13 5/4 35/45 
NIH070 BNC Active 25/M 1/5 5/2 25/25 
NIH082 BNC Active 25/M 10/4 3/3 40/40 
NIH085 BNC Active 22/M 5/7 4/3.5 30/30 
NIH086 BNC Active 21/M 9/12 3/2 35/45 
NIH090 BNC Active 34/M 16/7 2.5/3 18/35 
NIH092 BNC Active 23/M 8/10 5/2.5 35/30 
NIH096 BNC Active 20/M 13/10 2.5/2 40/35 
NIH100 BNC Active 25/M 1/2 3/2.5 45/40 
NIH104 BNC Active 19/M 10/6 2.5/3 30/40 
NIH134 BNC Active 20/M 13/6 3/2 50/45 
NIH139 BNC Active 21/M 0/0 4/2.5 30/35 
NIH141 BNC Active 21/M 35/6 4/5 18/45 
NIH142 BNC Active 18/F 10/5 5/5.5 30/30 
NIH148 BNC Active 21/F 15/6 5/3 40/35 
NIH153 BNC Active 22/M 14/8 2/4.5 25/30 
NIH157 BNC Active 22/F 3/1 2/2 35/40 
NIH160 BNC Active 19/M 2/7 4.5/2 35/35 
NIH180 BNC Active 18/F 3/0 4.5/7 20/12 
NIH184 BNC Active 18/M 6/6 2/2 30/50 
NIH185 BNC Active 32/F 0/3 3/3 35/35 
Averages 7.37/6.56 3.82/3.44 31.76/36.96 
Paired T Test (Within Subject) Significance 
t=1.396 
df=23 
p=0.176 
t=1.378 
df=24 
p=0.181 
t=-2.622 
df=23 
p=0.015 
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Table 3.2 Table of Sham Therapy Subject Information   
Subject Type Therapy Age/Gender CISS 
Before/After 
NPC 
Before/After 
PFV 
Before/After 
NIH016 BNC Placebo 20/F 17/10 5.5/4.5 35/45+ 
NIH023 BNC Placebo 18/M 17/15 5/3.5 25/45 
NIH030 BNC Placebo 22/M 4/2 3/3.5 16/20 
NIH052 BNC Placebo 23/M 10/11 4/4 35/18 
NIH053 BNC Placebo 18/F 11/7 2/3 30/35 
NIH054 BNC Placebo 19/M 19/23 2/3 45+/20 
NIH060 BNC Placebo 18/M 12/22 5.5/4 25/40 
NIH064 BNC Placebo 21/F 11/19 5/3.5 20/35 
NIH068 BNC Placebo 18/M 3/8 4/2.5 40/30 
NIH083 BNC Placebo 22/M 7/6 3/4 40/45 
NIH084 BNC Placebo 22/M 10/9 2.5/2 30/30 
NIH091 BNC Placebo 24/M 3/5 2/2.5 25/30 
NIH094 BNC Placebo 21/M 9/8 4.5/4.5 30/35 
NIH099 BNC Placebo 22/F 3/6 4/3.5 25/40 
NIH101 BNC Placebo 25/M 9/4 4/4.5 45/45 
NIH135 BNC Placebo 21/F 0/0 2/4 20/30 
NIH136 BNC Placebo 18/F 16/13 3/3.5 16/12 
NIH143 BNC Placebo 25/F 9/4 5/5.5 40/30 
NIH146 BNC Placebo 21/M 9/2 5/5 40/35 
NIH147 BNC Placebo 23/F 7/26 3/2 40/35 
NIH149 BNC Placebo 23/F 6/2 4/3.5 40/30 
NIH150 BNC Placebo 26/M 3/13 4/6.5 30/20 
NIH158 BNC Placebo 23/M 57/5 3/3.5 35/35 
NIH159 BNC Placebo 23/M 26/0 5/5.5 35/35 
NIH179 BNC Placebo 25/M 3/2 4/3 25/20 
Averages 8.96/8.88 3.76/3.78 30.92/31.25 
Paired T Test (Within Subject) 
t=0.083 
df=24 
p=0.934 
T=-0.093 
df=24 
p=0.927 
t=-0.497 
df=22 
p=0.624 
 
The active therapy BNC had a CISS of 6.56 ± 3.94, NPC of 3.44 ± 1.47, and PFV of 
36.96 ± 8.61 after therapy (Table 3.1). The sham therapy BNC had a CISS of 8.88 ± 7.33, 
NPC of 3.78 ± 1.09, and PFV of 31.25 ± 9.04 after therapy (Table 3.2). OBVAT therapy 
subjects saw slight improvement in CISS, NPC, and PFV while the sham therapy saw 
almost no change. The subjects where changes occurred were primarily from the OBVAT 
cohort. 
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3.2 Latency Results and Time to Peak Velocity Results 
Table A1 and A2 summarizes the values of latency and time to peak velocity respectively. 
These tables also show the results of the mixed ANOVA. For latency, out of 38 movements 
there were 11 (Con 28, Con 48, Div 126, DS Con 26, DS Con 812, DS Div 126, DS Div 
128, DS Div 84, FastCon 212, L2M5, and M2L5) movements that showed significant 
difference. 3 of the 11 (Div 126, DS Con 812, DS Div 128) showed difference by sex, 4 
(Con 28, Con 48, DS Div 126, and FastCon 212) showed by before/after therapy, and 5 
(DS Con 26, DS Div 84, FastCon212, L2M5, and M2L5) showed by therapy type. For time 
to peak velocity, there were 13 out of 38 (Con26, Con 28, Con 48, Div 62, DS Con 26, DS 
Div 84, FastCon 212, FastDiv 122, SlowDiv 126, SlowDiv 82, L2M5, M2L5, and R2M5) 
that had significant difference. 1 of the 13 (Con 28) showed difference by sex, 7 (DS Con 
26, DS Div 84, FastCon 212, FastDiv 122, SlowDiv 126, SlowDiv 82, and R2M5) showed 
by before/after therapy, and 6 (Con26, Con 28, Con 48, Div 62, L2M5, and M2L5) showed 
by therapy type. Post hoc analysis was only done on movements that showed significance 
in both before/after therapy and therapy type. There was one (FastCon212) for latency and 
none for time to peak velocity. When the post-hoc analysis was done, the one movement 
(FastCon 212) showed that OBVAT therapy made a significant difference in the latency 
before/after therapy. The mean latency from the fast convergence step ramp that was from 
2 to 12 degrees showed a statistically significant decrease in latency due to OBVAT 
therapy. Though the sham FastCon212 mean latency decreases, it is not statistically 
significant. The divergence movements with the same degrees of movement are also not 
statistically significant. 
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Figure 3.1 This figure shows the means and standard deviations for stepramp convergence and 
stepramp divergence movements for both the active and placebo therapies. 
 
3.3 Peak Velocity Results 
Table A3 summarizes the values of peak velocity. These tables also show the results of the 
mixed ANOVA. For time to peak velocity, there were 20 out of 38 (Con 26, Con 28, Con 
48, Con 610, Con 612, Con 812, Div 62, Div 84, DS Con 26, DS Con 28, DS Con 48, DS 
Con 612, DS Div 106, DS Div 126, DS Div 84, FastCon 212, SlowCon 28, SlowCon 612, 
SlowDiv 126, and SlowDiv 82) that had significant difference. 16 out of 20 (Con 26, Con 
28, Con 610, Con 612, Con 812, DS Con 26, DS Con 28, DS Con 48, DS Con 612, DS Div 
126, DS Div 84, FastCon 212, SlowCon 28, SlowCon 612, SlowDiv 126, and SlowDiv 82) 
showed difference by before/after therapy, 3 (DS Con 612, DS Div 106, and SlowDiv 82) 
showed difference by sex, and 14 (Con 26, Con 28, Con 48, Con 610, Con 812, DS Con 
26, DS Con 28, DS Con 48, DS Div 106, FastCon 212, SlowCon 28, and SlowCon 612) 
showed by therapy type. Post hoc analysis was only done on movements that showed 
** 
*         P<.05 
**       P<.01 
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significance in both before/after therapy and therapy type. There was 10 for peak velocity. 
When the post-hoc analysis was done, all ten movements (Con 26, Con 28, Con 610, Con 
812, DS Con 26, DS Con 28, DS Con 48, FastCon 212, SlowCon 28, and SlowCon 612) 
showed that OBVAT therapy made a significant difference between the before/after data. 
All ten movements showed a statistically significant increase in the peak velocity. The 
subjects that underwent the placebo therapy showed either no improvement or statistically 
insignificant changes (mostly negligible increases). Though the divergence movements 
saw, for the most part, higher peak velocities as well they were statistically insignificant. 
 
Figure 3.2 This figure shows the means and standard deviations for convergence and divergence 
movements for both the active and placebo therapies. 
 
** 
** 
** 
** 
*         P<.05 
**       P<.01 
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Figure 3.3 This figure shows the means and standard deviations for disappearing step 
convergence and disappearing step divergence movements for both the active and placebo 
therapies. 
 
Figure 3.4 This figure shows the means and standard deviations for stepramp convergence and 
stepramp divergence movements for both the active and placebo therapies. 
 
** ** 
** 
*         P<.05 
**       P<.01 
** ** ** 
*         P<.05 
**       P<.01 
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3.4 Response Amplitude and Final Amplitude Results 
Table A4 and A5 summarizes the values of response amplitude and final amplitude 
respectively. These tables also show the results of the mixed ANOVA. For response 
amplitude, there were 10 out of 38 (Con 28, Con 612, Con 812, DS Con 48, DS Con 612, 
DS Div 106, DS Div 128, SlowCon 28, M2L10, M2R5) that had significant difference. 7 
out of 10 (Con 28, Con 612, Con 812, DS Con 612, SlowCon 28, M2L10, and M2R5) 
showed difference by before/after therapy, 2 (DS Div 106 and DS Div 128) showed 
difference by sex, and 1 (DS Con 48) showed by therapy type. For final amplitude, there 
were 11 (Con 48, Div 82, Div 84, FastCon 212, SlowCon 28, FastDiv 122, SlowDiv 82, 
L2M10, M2L10, M2R10, R2M10) out of 38 that had significant difference. 10 out of 11 
(Con 48, Div 82, FastCon 212, SlowCon 28, FastDiv 122, SlowDiv 82, L2M10, M2L10, 
M2R10, R2M10) showed difference by before/after therapy, 3 (Con 48, Div 84, and 
SlowCon 28) showed difference by sex, and 7 (FastCon 212, FastDiv 122, SlowDiv 82, 
L2M10, M2L10, M2R10, R2M10) showed by therapy type. Post hoc analysis was only 
done on movements that showed significance in both before/after therapy and therapy type. 
There was none for response amplitude and seven for final amplitude. When the post-hoc 
analysis was done, all seven movements (FastCon 212, FastDiv 122, SlowDiv82, L2M10, 
M2L10, M2R10, and R2M10) showed that OBVAT therapy made a significant difference 
between the before/after data. The seven movements showed amplitudes closer to the 
target, if not at the target, amplitude post therapy. Their sham therapy counterparts showed 
negligible change in amplitude. 
 28 
 
Figure 3.5 This figure shows the means and standard deviations for stepramp convergence and 
stepramp divergence movements for both the active and placebo therapies. 
 
Figure 3.6 This figure shows the means and standard deviations for saccadic movements for both 
the active and placebo therapies. 
 
3.5 Main Sequence Ratio Results 
Table A6 summarizes the values of main sequence ratio. These tables also show the results 
of the mixed ANOVA. For main sequence ratio, there were 15 out of 38 (Con 28, Con 48, 
Con 610, Con 612, Div 62, Div 84, DS Con 48, DS Con 612, DS Div 128, DS Div 84, 
** 
** 
** 
*         P<.05 
**       P<.01 
** *
* 
** ** 
*         P<.05 
**       P<.01 
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FastCon 212, SlowCon 612, M2L5, M2R10, R2M5) that had significant difference. 5 out 
of 15 (Con 48, Con612, DS Con 48, DS Div 84, and SlowCon 612) showed difference by 
before/after therapy, 2 (DS Div 128 and M2R10) showed difference by sex, and 11 (Con 
28, Con 48, Con 610, Div 62, Div 84, DS Con 612, DS Div 84, FastCon 212, SlowCon 612, 
M2L5, and R2M5) showed by therapy type. Post hoc analysis was only done on 
movements that showed significance in both before/after therapy and therapy type. There 
was three for main sequence ratio. When the post-hoc analysis was done, only three 
movements (Con 48, DS Div 84, and SlowCon 612) showed that OBVAT therapy made a 
significant difference between the before/after data. OBVAT subject’s Con 48 showed a 
statistically significant increase in main sequence ratio, with their other convergence 
movements also increased but not significantly. Placebo subjects saw insignificant 
changes, either marginally increasing or decreasing. Placebo DS Div 84 and SlowCon 612 
showed significant increases in their ratios as well. All other movements showed 
insignificant increases or decreases. 
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Figure 3.7 This figure shows the means and standard deviations for convergence and divergence 
movements for both the active and placebo therapies. 
 
 
Figure 3.8 This figure shows the means and standard deviations for disappearing step 
convergence and disappearing step divergence movements for both the active and placebo 
therapies. 
** 
*         P<.05 
**       P<.01 
** 
*         P<.05 
**       P<.01 
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Figure 3.9 This figure shows the means and standard deviations for stepramp convergence and 
stepramp divergence movements for both the active and placebo therapies. 
 
 
 
 
 
 
 
 
 
 
 
 
** 
*         P<.05 
**       P<.01 
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CHAPTER 4 
DISCUSSION and CONCLUSIONS 
 
4.1 Discussion 
Peak Velocity showed significant differences in the before vs after therapy and the type of 
therapy in 10 of the 20 movements (Con 26, Con 28, Con 610, Con 812, DS Con 26, DS 
Con 28, DS Con 48, FastCon 212, SlowCon 28, and SlowCon 612). Response amplitude 
was significantly different in either before vs after, sex, or therapy type. This suggests that 
the FIC is improving.  As seen in previous studies, near convergence movements were 
faster than far15. For divergence, the reverse was true. Near divergence movements were 
slower than far divergence movements. The increase in peak velocities and response 
amplitude closer to target post therapy matches results seen in previous studies25. Final 
amplitude also saw the OBVAT subjects achieving the target amplitudes. 
An aspect to consider when analyzing the results of any data collected is to be wary 
that peak velocity can change as a function of the person’s phoria level 8,10,12,13,16,21,26,27. 
When trying to analyze, final amplitude is an excellent way to compare your results when 
there is no normative data. When shown, for example, a 4 degree step the response 
amplitude should be 4 degrees as well. This would be the ideal case. 
One difference of interest is between the convergence and divergence peak 
velocities. As seen in previous studies, convergence movements have higher velocities than 
the divergence movements9.  This evidence supports the hypothesis that the phoria (SFTS) 
acts as a “spring”. This spring accelerates the convergence movements but slows the 
divergence movements. The Dual Mode Theory states that disparity vergence is a two-
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component system 14,28-31. The Fusion Initiating Component (FIC) is a preprogrammed 
response18. It is responsible for moving the eyes towards the new target quickly, but it may 
not be precise or accurate. Preprogrammed control is a predetermined series of actions that 
the brain executes without any feedback from the external sources once the series of actions 
is initiated. The Fusion Sustaining Component (FSC) is different in that it is feedback 
controlled. It is responsible for moving the eyes from where they are currently located to 
the desired target. Feedback control means the brain will determine where the target is and 
where the eyes are currently located. The FSC then rotates the eyes toward the intended 
target until the eyes are located at or very close to the target. FIC modelling and signal 
processing show20 that it follows the velocity trace signal, and is hypothesized to be 
generated by the “velocity-encoding” burst cells as described in neurophysiology studies 
found near the oculomotor nucleus within the midbrain32. The FSC, on the other hand, 
mimics the “position-encoding” tonic cells which are distinct cells, also located in the 
midbrain32. The FIC is assessed using the vergence peak velocity. The FSC is assessed by 
the final amplitude. 
This study improves and adds to previous studies in a few ways. Daum’s42 study 
did not have as many subjects trained for as long of time. Daum also did not have a sham 
to compare the active therapy results to. This study utilized ramp stimuli and knowledge 
of the vergence response in order to determine effectiveness of the therapies. Ciuffreda’s43 
retrospective study revealed results about non-binocularly normal people undergoing 
therapy, while this study only studied BNCs (who did not have history of brain injury or 
any eye dysfunctions). This study expanded on Yang et al. 44 by testing not just latency, 
but 5 more parameters as well, all done using two groups of young adults placed into active 
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and sham therapy. This study built on Talasan et al. 21 by having a larger sample and by 
having the second group participate in sham therapy, helping to keep all of the subjects 
naïve as to whether or not they were receiving active therapy.  
One area of possible utilization of vision therapy on binocularly normal people is 
for sports. Sports require quick and accurate target acquisition. Sports vision training is an 
evolving field, and there are new techniques always being developed. There are some 
training procedures that work in component skill training33. Low-level visual instruments, 
perceptual-cognitive training instruments, visual-motor reaction training, and integrated 
sensorimotor batteries of behavioral tasks. Others believe that simulating live game 
situations creates the best sports vision training. Stroboscopic visual training, eye tracking 
and quiet eye (QE) training, and sports simulations and virtual reality platforms are used 
in these situations. Training to improve the symmetry of the left and right eye movements 
has been shown to be possible19 and might also improve their skills in their game. Previous 
studies have shown in baseball that the best hitters have the best “saccadic pursuit, and 
convergence abilities” 40. It was also shown that training could significantly improve 
batting ability41. The improvements in the controls suggest that OBVAT vision therapy 
may be used for sports enhancement. This can be done to improve athletic performance in 
many sports, especially ball sports. Sports ranging from football to ping pong require quick 
and accurate visual acquisition of the ball in order to catch or hit it. From this study, the 
improvements to the peak velocities of the subjects in OBVAT suggest that OBVAT could 
be used to improve the speed in which athletes can see their target. It has been shown that 
even short periods of training can provide long-term improvement to those who undergo 
it42. Improvement in healthy subjects can be translated to direct personalized procedures 
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that athletes could undergo to improve their visual performance. Mild TBI/concussions that 
may occur during play that may cause CI which can then also be treated using OBVAT17.  
 
4.2 Conclusions, Future Work, and Limitations 
This study shows that OBVAT on binocularly normal controls shows significant 
improvements to the vergence oculomotor system. Future work should include a similar 
study focused on subjects with CI to determine whether OBVAT significantly improves 
eye movements and therefore the visual system. This study could also be redone with 
people of different age groups. This study utilized mostly young adult students. This could 
be repeated with children or older adults to see how age affects a person’s eye movement 
parameters, especially in older adults in which presbyopia may have an effect. Aging is 
associated with a decrease in the magnitude of phoria adaptation but not the rate of 
adaptation or disparity vergence, but more can be done with this23. The FIC improvements 
shown suggest that the midbrain may be changing regarding “velocity-encoding” burst 
cells. A functional imaging study of all participants should be conducted to determine if 
there is actual physiological change between the OBVAT and OBPT subjects. This should 
also be translated into personalized therapy to better suit an individual’s needs. 
Some limitations of the study included subjects having to sit at a traditional 
haploscope for a certain amount of time to do the eye movement assessment. This also may 
have happened at any time of day, meaning that the subject’s alertness could affect their 
movements. A subject could get more tired as the assessment progressed, especially later 
in the day, which may negatively impact their movements. A future study could eliminate 
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that variable. Phoria was not controlled for each subject, meaning that they did not have 
personalized levels when doing the movements.  
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APPENDIX A 
STATISTICAL ANALYSIS 
Table A1 This table contains the statistics showing the factor, error df, and significance between-
factor (before vs after therapy), between-sex (M vs F), and between-therapy (OBVAT vs sham) for 
each movement’s latency. The tests with significant data are highlighted in green. 
 
Latency 
  F Error df Sig 
 
Con 26 
Factor 0.008 42 .929 
Sex 0.38 42 0.846 
Therapy 0.684 42 0.413 
Con 28 
Factor 10.771 42 0.002 
Sex 0.002 42 0.964 
Therapy 2.44 42 0.126 
Con 48 
Factor 18.168 43 0 
Sex 0.415 43 0.523 
Therapy 0.206 43 0.652 
Con 610 
Factor 0.468 42 0.498 
Sex 0.686 42 0.412 
Therapy 0.337 42 0.565 
Con 612 
Factor 3.689b 43 0.061 
Sex .570b 43 0.454 
Therapy .040b 43 0.843 
Con 812 
Factor 2.504b 42 .121 
Sex .824b 42 .369 
Therapy .048b 42 .828 
Div 106 
Factor .084b 42 .773 
Sex .543b 42 .465 
Therapy 4.056b 42 .050 
Div 126 
Factor 1.737b 40 .195 
Sex 8.315b 40 .006 
Therapy 3.803b 40 .058 
Div 128 
Factor 1.702 43 .199 
Sex 1.748 43 .193 
Therapy 0.132 43 .718 
Div 62 
Factor .176b 40 .677 
Sex .051b 40 .823 
Therapy .084b 40 .773 
Div 82 
Factor .326b 43 .571 
Sex .533b 43 .469 
Therapy .004b 43 .947 
Div 84 
Factor .337b 42 .565 
Sex .095b 42 .760 
Therapy .906b 42 .347 
DS Con 26 
Factor .260b 42 .613 
Sex 1.513b 42 .226 
Therapy 6.775b 42 .013 
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DS Con 28 
Factor 2.123b 45 .152 
Sex .622b 45 .435 
Therapy 1.967b 45 .168 
DS Con 48 
Factor .109b 45 .743 
Sex .299b 45 .587 
Therapy .056b 45 .815 
DS Con 610 
Factor 1.747894 41 .193 
Sex .815b 41 .788 
Therapy .062b 41 .805 
DS Con 612 
Factor .015b 41 .903 
Sex 2.345b 41 .133 
Therapy .656b 41 .423 
DS Con 812 
Factor .003b 44 .959 
Sex 5.140b 44 .028 
Therapy 2.917b 44 .095 
DS Div 106 
Factor .439b 44 .511 
Sex .689b 44 .411 
Therapy .850b 44 .361 
DS Div 126 
Factor 4.069b 44 .050 
Sex .007b 44 .935 
Therapy .765b 44 .386 
DS Div 128 
Factor .248b 43 .621 
Sex 5.299b 43 .026 
Therapy .437b 43 .512 
DS Div 62 
Factor .624b 43 .434 
Sex .031b 43 .860 
Therapy 1.235b 43 .273 
DS Div 82 
Factor .000b 45 .993 
Sex 3.120b 45 .084 
Therapy .829b 45 .367 
DS Div 84 
Factor .248b 47 .621 
Sex .817b 47 .371 
Therapy 4.204b 47 .046 
FastCon 212 
Factor 6.899b 39 .012 
Sex .006b 39 .940 
Therapy 4.144b 39 .049 
SlowCon 28 
Factor .063b 36 .803 
Sex .295b 36 .590 
Therapy 1.440b 36 .238 
SlowCon 612 
Factor 2.549b 41 .118 
Sex .038b 41 .846 
Therapy .629b 41 .432 
FastDiv 122 
Factor .007b 34 .931 
Sex .040b 34 .843 
Therapy 3.462b 34 .071 
SlowDiv 126 
Factor 3.620b 34 .066 
Sex .565b 34 .458 
Therapy 2.117b 34 .155 
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SlowDiv 82 
Factor 2.971b 39 .093 
Sex .009b 39 .923 
Therapy 2.233b 39 .143 
L2M10 
Factor .002b 44 .966 
Sex .032b 44 .859 
Therapy 2.511b 44 .120 
L2M5 
Factor .110b 46 .741 
Sex .014b 46 .907 
Therapy 6.677b 46 .013 
M2L10 
Factor 1.746b 42 .194 
Sex .451b 42 .506 
Therapy 1.293b 42 .262 
M2L5 
Factor .085b 45 .772 
Sex .163b 45 .688 
Therapy 8.761b 45 .005 
M2R10 
Factor 3.259b 45 .078 
Sex .046b 45 .831 
Therapy .269b 45 .606 
M2R5 
Factor .081b 44 .777 
Sex .387b 44 .537 
Therapy .099b 44 .755 
 
R2M10 
Factor .810b 46 .373 
Sex .043b 46 .837 
Therapy .488b 46 .488 
 
R2M5 
Factor 2.478b 45 .122 
Sex .154b 45 .697 
Therapy .045b 45 .834 
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Table A2 This table contains the statistics showing the factor, error df, and significance for 
between-factor (before vs after therapy), between-sex (M vs F), and between-therapy (OBVAT vs 
sham) for each movement’s time to peak velocity. The tests with significant data are highlighted in 
green. 
 
Time To Peak Velocity 
  F Error df Sig 
 
Con 26 
Factor 1.417b 42 0.241 
Sex .193b 42 0.663 
Therapy 10.651b 42 0.002 
Con 28 
Factor 3.780b 44 0.058 
Sex 5.471b 44 0.024 
Therapy 11.256b 44 0.002 
Con 48 
Factor 2.177b 47 0.147 
Sex .049b 47 0.825 
Therapy 7.080b 47 0.011 
Con 610 
Factor 1.340b 43 0.253 
Sex 1.122b 43 0.295 
Therapy .390b 43 0.535 
Con 612 
Factor .804b 41 0.375 
Sex .003b 41 0.956 
Therapy 1.869b 41 0.179 
Con 812 
Factor .794b 41 0.378 
Sex .779b 41 .383 
Therapy 2.883b 41 .097 
Div 106 
Factor .514b 40 .478 
Sex .063b 40 .803 
Therapy 1.934b 40 .172 
Div 126 
Factor .293b 37 .592 
Sex .072b 37 .789 
Therapy 2.996b 37 .092 
Div 128 
Factor .187b 41 .668 
Sex .298b 41 .588 
Therapy 2.046b 41 .160 
Div 62 
Factor .322b 41 .573 
Sex 1.607b 41 .212 
Therapy 8.702b 41 .005 
Div 82 
Factor .036b 42 .850 
Sex .200b 42 .657 
Therapy 1.514b 42 .225 
Div 84 
Factor .326b 40 .571 
Sex .235b 40 .631 
Therapy 3.306b 40 .077 
DS Con 26 
Factor 5.311b 29 .029 
Sex .001b 29 .974 
Therapy 1.290b 29 .265 
DS Con 28 
Factor .350b 36 .558 
Sex 1.812b 36 .187 
Therapy 3.032b 36 .090 
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DS Con 48 
Factor 2.869b 38 .099 
Sex 1.790b 38 .189 
Therapy .045b 38 .834 
DS Con 610 
Factor .609b 32 .441 
Sex .044b 32 .834 
Therapy .122b 32 .729 
DS Con 612 
Factor 1.447b 34 .237 
Sex .757b 34 .391 
Therapy .043b 34 .836 
DS Con 812 
Factor .021b 30 .885 
Sex .004b 30 .949 
Therapy 1.228b 30 .277 
DS Div 106 
Factor .247b 30 .623 
Sex .250b 30 .621 
Therapy .016b 30 .900 
DS Div 126 
Factor 1.632b 38 .209 
Sex 2.982b 38 .092 
Therapy 1.400b 38 .244 
DS Div 128 
Factor 2.332b 28 .138 
Sex .182b 28 .673 
Therapy .539b 28 .469 
DS Div 62 
Factor .308b 38 .582 
Sex .122b 38 .729 
Therapy .419b 38 .521 
DS Div 82 
Factor 1.312b 40 .259 
Sex 1.238b 40 .273 
Therapy .946b 40 .337 
DS Div 84 
Factor 4.650b 42 .037 
Sex .007b 42 .934 
Therapy .020b 42 .889 
FastCon 212 
Factor 11.272b 39 .002 
Sex .344b 39 .561 
Therapy .395b 39 .533 
SlowCon 28 
Factor .559b 35 .460 
Sex 1.869b 35 .180 
Therapy 1.719b 35 .198 
SlowCon 612 
Factor 1.776b 42 .190 
Sex .123b 42 .727 
Therapy 1.852b 42 .181 
FastDiv 122 
Factor 4.472b 36 .041 
Sex .176b 36 .677 
Therapy .101b 36 .753 
SlowDiv 126 
Factor 4.275b 38 .046 
Sex .216b 38 .645 
Therapy .391b 38 .535 
SlowDiv 82 
Factor 5.861b 40 .020 
Sex .048b 40 .827 
Therapy .571b 40 .454 
     
 42 
L2M10 
Factor .179b 43 .675 
Sex 2.220b 43 .144 
Therapy .281b 43 .599 
L2M5 
Factor .102b 43 .751 
Sex .414b 43 .523 
Therapy 4.588b 43 .038 
M2L10 
Factor .161b 43 .691 
Sex .059b 43 .809 
Therapy .267b 43 .608 
M2L5 
Factor .010b 44 .920 
Sex .329b 44 .569 
Therapy 6.912b 44 .012 
M2R10 
Factor 1.808b 47 .185 
Sex .373b 47 .544 
Therapy .008b 47 .931 
M2R5 
Factor .001b 43 .972 
Sex 1.058b 43 .310 
Therapy .229b 43 .635 
 
R2M10 
Factor .013b 45 .908 
Sex .257b 45 .615 
Therapy .350b 45 .557 
 
R2M5 
Factor 6.739b 45 .013 
Sex .263b 45 .610 
Therapy .404b 45 .528 
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Table A3 This table contains the statistics showing the factor, error df, and significance for 
between-factor (before vs after therapy), between-sex (M vs F), and between-therapy (OBVAT vs 
sham) for each movement’s peak velocity. The tests with significant data are highlighted in green. 
 
Peak Velocity 
  F Error df Sig 
 
Con 26 
Factor 6.278b 41 0.016 
Sex 1.197b 41 0.280 
Therapy 6.386b 41 0.015 
Con 28 
Factor 8.910b 42 0.005 
Sex .442b 42 0.510 
Therapy 13.090b 42 0.001 
Con 48 
Factor 2.998b 45 0.090 
Sex .030b 45 0.864 
Therapy 10.359b 45 0.002 
Con 610 
Factor 4.094b 41 0.050 
Sex .091b 41 0.765 
Therapy 4.438b 41 0.041 
Con 612 
Factor 13.188b 42 0.001 
Sex .945b 42 0.337 
Therapy 2.644b 42 0.111 
Con 812 
Factor 6.755b 43 0.013 
Sex .000b 43 .991 
Therapy 7.111b 43 .011 
Div 106 
Factor .085b 41 .772 
Sex .309b 41 .581 
Therapy .254b 41 .617 
Div 126 
Factor 1.440b 41 .237 
Sex 2.973b 41 .092 
Therapy 3.127b 41 .084 
Div 128 
Factor 2.351b 42 .133 
Sex .658b 42 .422 
Therapy .513b 42 .478 
Div 62 
Factor 2.054b 41 .159 
Sex .221b 41 .641 
Therapy 7.176b 41 .011 
Div 82 
Factor .542b 44 .465 
Sex .044b 44 .836 
Therapy 3.256b 44 .078 
Div 84 
Factor 1.187b 42 .282 
Sex .017b 42 .897 
Therapy 4.504b 42 .040 
DS Con 26 
Factor 7.565b 39 .009 
Sex .108b 39 .745 
Therapy 5.000b 39 .031 
DS Con 28 
Factor 4.691b 40 .036 
Sex .232b 40 .633 
Therapy 4.910b 40 .032 
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DS Con 48 
Factor 5.038b 40 .030 
Sex .077b 40 .782 
Therapy 9.872b 40 .003 
DS Con 610 
Factor 3.494b 35 .070 
Sex .306b 35 .584 
Therapy .117b 35 .734 
DS Con 612 
Factor 8.895b 37 .005 
Sex 4.300b 37 .045 
Therapy .818b 37 .372 
DS Con 812 
Factor 2.416b 40 .128 
Sex .235b 40 .630 
Therapy 1.095b 40 .302 
DS Div 106 
Factor .094b 40 .761 
Sex 4.121b 40 .049 
Therapy 4.531b 40 .039 
DS Div 126 
Factor 6.793b 41 .013 
Sex .033b 41 .857 
Therapy 2.868b 41 .098 
DS Div 128 
Factor 2.724b 38 .107 
Sex .877b 38 .355 
Therapy 2.484b 38 .123 
DS Div 62 
Factor .448b 39 .507 
Sex .001b 39 .981 
Therapy .715b 39 .403 
DS Div 82 
Factor 1.428b 40 .239 
Sex .258b 40 .615 
Therapy .407b 40 .527 
DS Div 84 
Factor 11.147b 42 .002 
Sex 1.838b 42 .182 
Therapy .053b 42 .818 
FastCon 212 
Factor 8.753b 44 .005 
Sex .263b 44 .611 
Therapy 10.450b 44 .002 
SlowCon 28 
Factor 8.124b 40 .007 
Sex .506b 40 .481 
Therapy 5.521b 40 .024 
SlowCon 612 
Factor 4.726b 42 .035 
Sex .363b 42 .550 
Therapy 14.408b 42 .000 
FastDiv 122 
Factor 1.390b 45 .245 
Sex .503b 45 .482 
Therapy 2.834b 45 .099 
SlowDiv 126 
Factor 10.455b 43 .002 
Sex .230b 43 .634 
Therapy 1.598b 43 .213 
SlowDiv 82 
Factor 8.839b 42 .005 
Sex 4.481b 42 .040 
Therapy 3.627b 42 .064 
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L2M10 
Factor .389b 44 .536 
Sex .232b 44 .633 
Therapy .377b 44 .542 
L2M5 
Factor .749b 43 .392 
Sex 1.725b 43 .196 
Therapy .007b 43 .933 
M2L10 
Factor 1.234b 42 .273 
Sex .042b 42 .839 
Therapy 3.910b 42 .055 
M2L5 
Factor 1.806b 42 .186 
Sex 1.275b 42 .265 
Therapy .311b 42 .580 
M2R10 
Factor 3.939b 43 .054 
Sex 1.335b 43 .254 
Therapy .531b 43 .470 
M2R5 
Factor .650b 43 .424 
Sex .191b 43 .664 
Therapy .041b 43 .840 
 
R2M10 
Factor .499b 44 .484 
Sex 1.587b 44 .214 
Therapy .198b 44 .659 
 
R2M5 
Factor 2.372b 43 .131 
Sex 1.447b 43 .236 
Therapy .511b 43 .479 
 
 
 
 
 
 
 
 
 
 
 
 46 
Table A4 This table contains the statistics showing the factor, error df, and significance between-
factor (before vs after therapy), between-sex (M vs F), and between-therapy (OBVAT vs sham) for 
each movement’s response amplitude. The tests with significant data are highlighted in green. 
 
Response Amplitude 
  F Error df Sig 
 
Con 26 
Factor 3.132b 41 0.0842 
Sex .001b 41 0.9758 
Therapy .495b 41 0.4857 
Con 28 
Factor 6.665b 43 0.0133 
Sex .655b 43 0.4229 
Therapy 3.153b 43 0.0829 
Con 48 
Factor 3.110b 42 0.0851 
Sex .017b 42 0.8969 
Therapy .268b 42 0.6076 
Con 610 
Factor 2.482b 40 0.1231 
Sex .046b 40 0.8319 
Therapy .726b 40 0.3991 
Con 612 
Factor 6.496b 40 0.0148 
Sex 1.710b 40 0.1984 
Therapy 1.556b 40 0.2195 
Con 812 
Factor 8.376b 44 0.0059 
Sex 2.049b 44 .159 
Therapy .745b 44 .393 
Div 106 
Factor .859b 44 .359 
Sex 1.508b 44 .226 
Therapy 1.184b 44 .283 
Div 126 
Factor .588b 43 .447 
Sex .006b 43 .940 
Therapy 1.766b 43 .191 
Div 128 
Factor .170b 41 .682 
Sex 2.036b 41 .161 
Therapy .010b 41 .920 
Div 62 
Factor 2.254b 44 .140 
Sex .006b 44 .939 
Therapy .108b 44 .745 
Div 82 
Factor 3.264b 44 .078 
Sex .335b 44 .566 
Therapy .326b 44 .571 
Div 84 
Factor 1.234b 42 .273 
Sex .645b 42 .427 
Therapy .002b 42 .961 
DS Con 26 
Factor 3.540b 39 .067 
Sex .000b 39 .988 
Therapy 1.246b 39 .271 
DS Con 28 
Factor 1.223b 41 .275 
Sex 1.152b 41 .289 
Therapy 1.379b 41 .247 
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DS Con 48 
Factor .788b 41 .380 
Sex .237b 41 .629 
Therapy 5.766b 41 .021 
DS Con 610 
Factor 2.009b 35 .165 
Sex .153b 35 .698 
Therapy .000b 35 .998 
DS Con 612 
Factor 4.904b 37 .033 
Sex 3.126b 37 .085 
Therapy .083b 37 .775 
DS Con 812 
Factor 2.433b 40 .127 
Sex 1.389b 40 .245 
Therapy .130b 40 .721 
DS Div 106 
Factor 2.163b 40 .149 
Sex 8.606b 40 .006 
Therapy 4.037b 40 .051 
DS Div 126 
Factor 3.939b 41 .054 
Sex .003b 41 .954 
Therapy .241b 41 .626 
DS Div 128 
Factor 1.120b 41 .296 
Sex 4.556b 41 .039 
Therapy 1.748b 41 .193 
DS Div 62 
Factor 1.286b 40 .264 
Sex 2.058b 40 .159 
Therapy .388b 40 .537 
DS Div 82 
Factor 1.085b 43 .303 
Sex .163b 43 .688 
Therapy .037b 43 .848 
DS Div 84 
Factor .030b 44 .863 
Sex 1.821b 44 .184 
Therapy 2.468b 44 .123 
FastCon 212 
Factor .737b 44 .395 
Sex .600b 44 .443 
Therapy 3.906b 44 .054 
SlowCon 28 
Factor 4.152b 41 .048 
Sex .078b 41 .781 
Therapy 3.187b 41 .082 
SlowCon 612 
Factor .250b 40 .620 
Sex .256b 40 .616 
Therapy .946b 40 .337 
FastDiv 122 
Factor .131b 41 .719 
Sex .856b 41 .360 
Therapy .096b 41 .758 
SlowDiv 126 
Factor 1.691b 42 .201 
Sex .051b 42 .823 
Therapy .129b 42 .721 
SlowDiv 82 
Factor 3.284b 43 .077 
Sex 1.307b 43 .259 
Therapy .005b 43 .941 
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L2M10 
Factor 3.583b 43 .065 
Sex .007b 43 .932 
Therapy 2.872b 43 .097 
L2M5 
Factor 1.068b 44 .307 
Sex 3.446b 44 .070 
Therapy .378b 44 .542 
M2L10 
Factor 4.861b 44 .033 
Sex .494b 44 .486 
Therapy 1.739b 44 .194 
M2L5 
Factor 2.699b 45 .107 
Sex .772b 45 .384 
Therapy 2.531b 45 .119 
M2R10 
Factor 3.098b 42 .086 
Sex .920b 42 .343 
Therapy 3.629b 42 .064 
M2R5 
Factor 7.159b 43 .011 
Sex 1.563b 43 .218 
Therapy .656b 43 .422 
 
R2M10 
Factor 1.496b 42 .228 
Sex .269b 42 .606 
Therapy 1.146b 42 .290 
 
R2M5 
Factor 2.042b 43 .160 
Sex .544b 43 .465 
Therapy .015b 43 .903 
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Table A5 This table contains the statistics showing the factor, error df, and significance for 
between-factor (before vs after therapy), between-sex (M vs F), and between-therapy (OBVAT vs 
sham) for each movement’s final amplitude. The tests with significant data are highlighted in green. 
Disappearing steps do not present stimuli so there is no target present during the final amplitude. 
 
Final Amplitude 
  F Error df Sig 
 
Con 26 
Factor .028b 37 0.869 
Sex .001b 37 0.979 
Therapy 1.168b 37 0.287 
Con 28 
Factor 2.692b 41 0.109 
Sex .025b 41 0.876 
Therapy .804b 41 0.375 
Con 48 
Factor 4.250b 41 0.046 
Sex 10.254b 41 0.003 
Therapy .729b 41 0.398 
Con 610 
Factor 2.443b 38 0.126 
Sex 1.998b 38 0.166 
Therapy .295b 38 0.590 
Con 612 
Factor 3.124b 40 0.085 
Sex .634b 40 0.430 
Therapy 2.351b 40 0.133 
Con 812 
Factor .079b 39 0.781 
Sex .948b 39 .336 
Therapy .334b 39 .567 
Div 106 
Factor .070b 41 .792 
Sex 2.760b 41 .104 
Therapy .342b 41 .562 
Div 126 
Factor 1.024b 40 .318 
Sex .215b 40 .645 
Therapy .394b 40 .534 
Div 128 
Factor .001b 38 .974 
Sex .038b 38 .846 
Therapy 2.796b 38 .103 
Div 62 
Factor .926b 37 .342 
Sex .092b 37 .764 
Therapy .284b 37 .598 
Div 82 
Factor 8.535b 41 .006 
Sex .851b 41 .362 
Therapy 1.006b 41 .322 
Div 84 
Factor .275b  .603 
Sex 12.701b  .001 
Therapy .396b  .533 
DS Con 26 
Factor    
Sex    
Therapy    
DS Con 28 
Factor    
Sex    
Therapy    
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DS Con 48 
Factor    
Sex    
Therapy    
DS Con 610 
Factor    
Sex    
Therapy    
DS Con 612 
Factor    
Sex    
Therapy    
DS Con 812 
Factor    
Sex    
Therapy    
DS Div 106 
Factor    
Sex    
Therapy    
DS Div 126 
Factor    
Sex    
Therapy    
DS Div 128 
Factor    
Sex    
Therapy    
DS Div 62 
Factor    
Sex    
Therapy    
DS Div 82 
Factor    
Sex    
Therapy    
DS Div 84 
Factor    
Sex    
Therapy    
FastCon 212 
Factor 6.800b 40 .013 
Sex .037b 40 .849 
Therapy 5.462b 40 .025 
SlowCon 28 
Factor 4.768b 38 .035 
Sex 4.375b 38 .043 
Therapy .166b 38 .686 
SlowCon 612 
Factor .322b 42 .574 
Sex .000b 42 .991 
Therapy 3.576b 42 .066 
FastDiv 122 
Factor 13.310b 40 .001 
Sex .056b 40 .814 
Therapy 6.678b 40 .014 
SlowDiv 126 
Factor .094b 40 .761 
Sex .043b 40 .836 
Therapy 3.670b 40 .063 
SlowDiv 82 
Factor 6.360b 44 .015 
Sex .720b 44 .401 
Therapy 5.144b 44 .028 
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L2M10 
Factor 4.176b 40 .048 
Sex .031b 40 .860 
Therapy 8.542b 40 .006 
L2M5 
Factor 1.221b 42 .275 
Sex .002b 42 .968 
Therapy 1.459b 42 .234 
M2L10 
Factor 4.731b 41 .035 
Sex 1.295b 41 .262 
Therapy 6.413b 41 .015 
M2L5 
Factor 3.558b 42 .066 
Sex 1.010b 42 .321 
Therapy 2.394b 42 .129 
M2R10 
Factor 5.191b 44 .028 
Sex .388b 44 .537 
Therapy 11.945b 44 .001 
M2R5 
Factor 2.970b 42 .092 
Sex 2.270b 42 .139 
Therapy 3.286b 42 .077 
 
R2M10 
Factor 5.514b 41 .024 
Sex .327b 41 .570 
Therapy 4.760b 41 .035 
 
R2M5 
Factor .076b 44 .784 
Sex .052b 44 .820 
Therapy 3.653b 44 .063 
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Table A6 This table contains the statistics showing the factor, error df, and significance for 
between-factor (before vs after therapy), between-sex (M vs F), and between-therapy (OBVAT vs 
sham) for each movement’s main sequence ratio. The tests with significant data are highlighted in 
green. 
 
Main Sequence Ratio 
  F Error df Sig 
 
Con 26 
Factor .517b 43 0.476 
Sex 1.429b 43 0.239 
Therapy 3.300b 43 0.076 
Con 28 
Factor .474b 43 0.495 
Sex .170b 43 0.682 
Therapy 4.566b 43 0.038 
Con 48 
Factor 4.291b 45 0.044 
Sex 1.740b 45 0.194 
Therapy 7.270b 45 0.010 
Con 610 
Factor .083b 40 0.775 
Sex .972b 40 0.330 
Therapy 13.016b 40 0.001 
Con 612 
Factor 4.243b 45 0.045 
Sex 1.424b 45 0.239 
Therapy .424b 45 0.518 
Con 812 
Factor .158b 41 0.693 
Sex .082b 41 .776 
Therapy 2.156b 41 .150 
Div 106 
Factor .963b 40 .332 
Sex .133b 40 .718 
Therapy 1.343b 40 .253 
Div 126 
Factor 3.198b 39 .082 
Sex .059b 39 .810 
Therapy .183b 39 .671 
Div 128 
Factor 1.059b 42 .309 
Sex .274b 42 .603 
Therapy .018b 42 .894 
Div 62 
Factor .056b 40 .814 
Sex .094b 40 .761 
Therapy 5.322b 40 .026 
Div 82 
Factor 2.243b 43 .141 
Sex .291b 43 .592 
Therapy .402b 43 .529 
Div 84 
Factor 1.931b 41 .172 
Sex .046b 41 .831 
Therapy 9.195b 41 .004 
DS Con 26 
Factor 1.592b 37.000 .215 
Sex .857b 37.000 .360 
Therapy .012b 37.000 .914 
DS Con 28 
Factor .000b 40.000 .996 
Sex .065b 40.000 .800 
Therapy .828b 40.000 .368 
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DS Con 48 
Factor 7.320b 38.000 .010 
Sex .613b 38.000 .439 
Therapy .431b 38.000 .516 
DS Con 610 
Factor .874b 34.000 .356 
Sex .424b 34.000 .519 
Therapy .000b 34.000 .985 
DS Con 612 
Factor 1.659b 34.000 .206 
Sex .568b 34.000 .456 
Therapy 9.604b 34.000 .004 
DS Con 812 
Factor 1.054b 39.000 .311 
Sex .085b 39.000 .772 
Therapy .022b 39.000 .884 
DS Div 106 
Factor 1.836b 37.000 .184 
Sex 2.477b 37.000 .124 
Therapy 1.284b 37.000 .264 
DS Div 126 
Factor .309b 38.000 .582 
Sex .279b 38.000 .601 
Therapy .029b 38.000 .866 
DS Div 128 
Factor 1.334b 37.000 .255 
Sex 7.205b 37.000 .011 
Therapy 1.572b 37.000 .218 
DS Div 62 
Factor 3.281b 40.000 .078 
Sex 3.603b 40.000 .065 
Therapy .070b 40.000 .792 
DS Div 82 
Factor .321b 41.000 .574 
Sex .012b 41.000 .913 
Therapy 1.396b 41.000 .244 
DS Div 84 
Factor 9.879b 40.000 .003 
Sex 3.324b 40.000 .076 
Therapy 5.799b 40.000 .021 
FastCon 212 
Factor .011b 38.000 .915 
Sex .000b 38.000 .986 
Therapy 9.011b 38.000 .005 
SlowCon 28 
Factor .988b 41.000 .326 
Sex .229b 41.000 .635 
Therapy .499b 41.000 .484 
SlowCon 612 
Factor 18.788b 39.000 .000 
Sex 3.271b 39.000 .078 
Therapy 4.280b 39.000 .045 
FastDiv 122 
Factor 1.847b 40.000 .182 
Sex .801b 40.000 .376 
Therapy 1.229b 40.000 .274 
SlowDiv 126 
Factor 3.855b 42.000 .056 
Sex 1.987b 42.000 .166 
Therapy .372b 42.000 .545 
SlowDiv 82 
Factor .133b 43.000 .717 
Sex .542b 43.000 .466 
Therapy .083b 43.000 .775 
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L2M10 
Factor .296b 42.000 .590 
Sex .563b 42.000 .457 
Therapy 1.282b 42.000 .264 
L2M5 
Factor .047b 42.000 .830 
Sex .114b 42.000 .737 
Therapy 1.213b 42.000 .277 
M2L10 
Factor .009b 41.000 .925 
Sex .396b 41.000 .533 
Therapy 1.631b 41.000 .209 
M2L5 
Factor .059b 42.000 .809 
Sex .388b 42.000 .537 
Therapy 4.278b 42.000 .045 
M2R10 
Factor 2.686b 43.000 .109 
Sex 4.688b 43.000 .036 
Therapy 1.900b 43.000 .175 
M2R5 
Factor .919b 43.000 .343 
Sex .168b 43.000 .684 
Therapy .563b 43.000 .457 
 
R2M10 
Factor .023b 41.000 .880 
Sex 1.314b 41.000 .258 
Therapy .307b 41.000 .583 
 
R2M5 
Factor .110b 43.000 .741 
Sex 1.196b 43.000 .280 
Therapy 4.204b 43.000 .046 
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Table A7 This table contains the statistics showing the factor, error df, and significance for factor, 
sex, and therapy for latency movements that show significance in either Factor (before vs after), 
between-Sex, and/or between-Therapy (OBVAT vs Sham). The tests with significant Factor data 
are highlighted in green. The tests with significant between-sex data are highlighted in blue. The 
tests with significant between-therapy data are highlighted in yellow. Tests with significance seen 
in both Factor and Therapy are highlighted orange. 
 
Latency 
  F Error df Sig 
Con 28 
Factor 10.771 42 0.002 
Sex 0.002 42 0.964 
Therapy 2.44 42 0.126 
Con 48 
Factor 18.168 43 0 
Sex 0.415 43 0.523 
Therapy 0.206 43 0.652 
Div 126 
Factor 1.737b 40 .195 
Sex 8.315b 40 .006 
Therapy 3.803b 40 .058 
DS Con 26 
Factor .260b 42 .613 
Sex 1.513b 42 .226 
Therapy 6.775b 42 .013 
DS Con 812 
Factor .003b 44 .959 
Sex 5.140b 44 .028 
Therapy 2.917b 44 .095 
DS Div 126 
Factor 4.069b 44 .050 
Sex .007b 44 .935 
Therapy .765b 44 .386 
DS Div 128 
Factor .248b 43 .621 
Sex 5.299b 43 .026 
Therapy .437b 43 .512 
DS Div 84 
Factor .248b 47 .621 
Sex .817b 47 .371 
Therapy 4.204b 47 .046 
FastCon 212 
Factor 6.899b 39 .012 
Sex .006b 39 .940 
Therapy 4.144b 39 .049 
L2M5 
Factor .110b 46 .741 
Sex .014b 46 .907 
Therapy 6.677b 46 .013 
M2L5 
Factor .085b 45 .772 
Sex .163b 45 .688 
Therapy 8.761b 45 .005 
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Table A8 This table contains the statistics showing the factor, error df, and significance for factor, 
sex, and therapy for time to peak velocity movements that show significance in either Factor (before 
vs after), between-Sex, and/or between-Therapy (OBVAT vs Sham). The tests with significant 
Factor data are highlighted in green. The tests with significant between-sex data are highlighted in 
blue. The tests with significant between-therapy data are highlighted in yellow. Tests with 
significance seen in both Factor and Therapy are highlighted orange. 
 
Time to Peak Velocity 
  F Error df Sig 
Con 26 
Factor 1.417b 42 0.241 
Sex .193b 42 0.663 
Therapy 10.651b 42 0.002 
Con 28 
Factor 3.780b 44 0.058 
Sex 5.471b 44 0.024 
Therapy 11.256b 44 0.002 
Con 48 
Factor 2.177b 47 0.147 
Sex .049b 47 0.825 
Therapy 7.080b 47 0.011 
Div 62 
Factor .322b 41 .573 
Sex 1.607b 41 .212 
Therapy 8.702b 41 .005 
DS Con 26 
Factor 5.311b 29 .029 
Sex .001b 29 .974 
Therapy 1.290b 29 .265 
DS Div 84 
Factor 4.650b 42 .037 
Sex .007b 42 .934 
Therapy .020b 42 .889 
FastCon 212 
Factor 11.272b 39 .002 
Sex .344b 39 .561 
Therapy .395b 39 .533 
FastDiv 122 
Factor 4.472b 36 .041 
Sex .176b 36 .677 
Therapy .101b 36 .753 
SlowDiv 126 
Factor 4.275b 38 .046 
Sex .216b 38 .645 
Therapy .391b 38 .535 
SlowDiv 82 
Factor 5.861b 40 .020 
Sex .048b 40 .827 
Therapy .571b 40 .454 
L2M5 
Factor .102b 43 .751 
Sex .414b 43 .523 
Therapy 4.588b 43 .038 
M2L5 
Factor .010b 44 .920 
Sex .329b 44 .569 
Therapy 6.912b 44 .012 
R2M5 
Factor 6.739b 45 .013 
Sex .263b 45 .610 
Therapy .404b 45 .528 
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Table A9 This table contains the statistics showing the factor, error df, and significance for factor, 
sex, and therapy for peak velocity movements that show significance in either Factor (before vs 
after), between-Sex, and/or between-Therapy (OBVAT vs Sham). The tests with significant Factor 
data are highlighted in green. The tests with significant between-sex data are highlighted in blue. 
The tests with significant between-therapy data are highlighted in yellow. Tests with significance 
seen in both Factor and Therapy are highlighted orange. 
 
Peak Velocity 
  F Error df Sig 
Con 26 
Factor 6.278b 41 0.016 
Sex 1.197b 41 0.280 
Therapy 6.386b 41 0.015 
Con 28 
Factor 8.910b 42 0.005 
Sex .442b 42 0.510 
Therapy 13.090b 42 0.001 
Con 48 
Factor 2.998b 45 0.090 
Sex .030b 45 0.864 
Therapy 10.359b 45 0.002 
Con 610 
Factor 4.094b 41 0.050 
Sex .091b 41 0.765 
Therapy 4.438b 41 0.041 
Con 612 
Factor 13.188b 42 0.001 
Sex .945b 42 0.337 
Therapy 2.644b 42 0.111 
Con 812 
Factor 6.755b 43 0.013 
Sex .000b 43 .991 
Therapy 7.111b 43 .011 
Div 62 
Factor 2.054b 41 .159 
Sex .221b 41 .641 
Therapy 7.176b 41 .011 
Div 84 
Factor 1.187b 42 .282 
Sex .017b 42 .897 
Therapy 4.504b 42 .040 
DS Con 26 
Factor 7.565b 39 .009 
Sex .108b 39 .745 
Therapy 5.000b 39 .031 
DS Con 28 
Factor 4.691b 40 .036 
Sex .232b 40 .633 
Therapy 4.910b 40 .032 
DS Con 48 
Factor 5.038b 40 .030 
Sex .077b 40 .782 
Therapy 9.872b 40 .003 
DS Con 612 
Factor 8.895b 37 .005 
Sex 4.300b 37 .045 
Therapy .818b 37 .372 
DS Div 106 
Factor .094b 40 .761 
Sex 4.121b 40 .049 
Therapy 4.531b 40 .039 
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DS Div 126 
Factor 6.793b 41 .013 
Sex .033b 41 .857 
Therapy 2.868b 41 .098 
DS Div 84 
Factor 11.147b 42 .002 
Sex 1.838b 42 .182 
Therapy .053b 42 .818 
FastCon 212 
Factor 8.753b 44 .005 
Sex .263b 44 .611 
Therapy 10.450b 44 .002 
SlowCon 28 
Factor 8.124b 40 .007 
Sex .506b 40 .481 
Therapy 5.521b 40 .024 
SlowCon 612 
Factor 4.726b 42 .035 
Sex .363b 42 .550 
Therapy 14.408b 42 .000 
SlowDiv 126 
Factor 10.455b 43 .002 
Sex .230b 43 .634 
Therapy 1.598b 43 .213 
SlowDiv 82 
Factor 8.839b 42 .005 
Sex 4.481b 42 .040 
Therapy 3.627b 42 .064 
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Table A10 This table contains the statistics showing the factor, error df, and significance for factor, 
sex, and therapy for response amplitude movements that show significance in either Factor (before 
vs after), between-Sex, and/or between-Therapy (OBVAT vs Sham). The tests with significant 
Factor data are highlighted in green. The tests with significant between-sex data are highlighted in 
blue. The tests with significant between-therapy data are highlighted in yellow. Tests with 
significance seen in both Factor and Therapy are highlighted orange. 
 
Response Amplitude 
  F Error df Sig 
Con 28 
Factor 6.665b 43 0.0133 
Sex .655b 43 0.4229 
Therapy 3.153b 43 0.0829 
Con 612 
Factor 6.496b 40 0.0148 
Sex 1.710b 40 0.1984 
Therapy 1.556b 40 0.2195 
Con 812 
Factor 8.376b 44 0.0059 
Sex 2.049b 44 .159 
Therapy .745b 44 .393 
DS Con 48 
Factor .788b 41 .380 
Sex .237b 41 .629 
Therapy 5.766b 41 .021 
DS Con 612 
Factor 4.904b 37 .033 
Sex 3.126b 37 .085 
Therapy .083b 37 .775 
DS Div 106 
Factor 2.163b 40 .149 
Sex 8.606b 40 .006 
Therapy 4.037b 40 .051 
DS Div 128 
Factor 1.120b 41 .296 
Sex 4.556b 41 .039 
Therapy 1.748b 41 .193 
SlowCon 28 
Factor 4.152b 41 .048 
Sex .078b 41 .781 
Therapy 3.187b 41 .082 
M2L10 
Factor 4.861b 44 .033 
Sex .494b 44 .486 
Therapy 1.739b 44 .194 
M2R5 
Factor 7.159b 43 .011 
Sex 1.563b 43 .218 
Therapy .656b 43 .422 
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Table A11 This table contains the statistics showing the factor, error df, and significance for factor, 
sex, and therapy for final amplitude movements that show significance in either Factor (before vs 
after), between-Sex, and/or between-Therapy (OBVAT vs Sham). The tests with significant Factor 
data are highlighted in green. The tests with significant between-sex data are highlighted in blue. 
The tests with significant between-therapy data are highlighted in yellow. Tests with significance 
seen in both Factor and Therapy are highlighted orange. 
 
Final Amplitude 
  F Error df Sig 
Con 48 
Factor 4.250b 41 0.046 
Sex 10.254b 41 0.003 
Therapy .729b 41 0.398 
Div 82 
Factor 8.535b 41 .006 
Sex .851b 41 .362 
Therapy 1.006b 41 .322 
Div 84 
Factor .275b 39 .603 
Sex 12.701b 39 .001 
Therapy .396b 39 .533 
FastCon 212 
Factor 6.800b 40 .013 
Sex .037b 40 .849 
Therapy 5.462b 40 .025 
SlowCon 28 
Factor 4.768b 38 .035 
Sex 4.375b 38 .043 
Therapy .166b 38 .686 
FastDiv 122 
Factor 13.310b 40 .001 
Sex .056b 40 .814 
Therapy 6.678b 40 .014 
SlowDiv 82 
Factor 6.360b 44 .015 
Sex .720b 44 .401 
Therapy 5.144b 44 .028 
L2M10 
Factor 4.176b 40 .048 
Sex .031b 40 .860 
Therapy 8.542b 40 .006 
M2L10 
Factor 4.731b 41 .035 
Sex 1.295b 41 .262 
Therapy 6.413b 41 .015 
M2R10 
Factor 5.191b 44 .028 
Sex .388b 44 .537 
Therapy 11.945b 44 .001 
R2M10 
Factor 5.514b 41 .024 
Sex .327b 41 .570 
Therapy 4.760b 41 .035 
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Table A12 This table contains the statistics showing the factor, error df, and significance for factor, 
sex, and therapy for main sequence ratio movements that show significance in either Factor (before 
vs after), between-Sex, and/or between-Therapy (OBVAT vs Sham). The tests with significant 
Factor data are highlighted in green. The tests with significant between-sex data are highlighted in 
blue. The tests with significant between-therapy data are highlighted in yellow. Tests with 
significance seen in both Factor and Therapy are highlighted orange. 
 
Main Sequence Ratio 
  F Error df Sig 
Con 28 
Factor .474b 43 0.495 
Sex .170b 43 0.682 
Therapy 4.566b 43 0.038 
Con 48 
Factor 4.291b 45 0.044 
Sex 1.740b 45 0.194 
Therapy 7.270b 45 0.010 
Con 610 
Factor .083b 40 0.775 
Sex .972b 40 0.330 
Therapy 13.016b 40 0.001 
Con 612 
Factor 4.243b 45 0.045 
Sex 1.424b 45 0.239 
Therapy .424b 45 0.518 
Div 62 
Factor .056b 40 .814 
Sex .094b 40 .761 
Therapy 5.322b 40 .026 
Div 84 
Factor 1.931b 41 .172 
Sex .046b 41 .831 
Therapy 9.195b 41 .004 
DS Con 48 
Factor 7.320b 38 .010 
Sex .613b 38 .439 
Therapy .431b 38 .516 
DS Con 612 
Factor 1.659b 34 .206 
Sex .568b 34 .456 
Therapy 9.604b 34 .004 
DS Div 128 
Factor 1.334b 37 .255 
Sex 7.205b 37 .011 
Therapy 1.572b 37 .218 
DS Div 84 
Factor 9.879b 40 .003 
Sex 3.324b 40 .076 
Therapy 5.799b 40 .021 
FastCon 212 
Factor .011b 38 .915 
Sex .000b 38 .986 
Therapy 9.011b 38 .005 
SlowCon 612 
Factor 18.788b 39 .000 
Sex 3.271b 39 .078 
Therapy 4.280b 39 .045 
M2L5 
Factor .059b 42 .809 
Sex .388b 42 .537 
Therapy 4.278b 42 .045 
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M2R10 
Factor 2.686b 43 .109 
Sex 4.688b 43 .036 
Therapy 1.900b 43 .175 
R2M5 
Factor .110b 43 .741 
Sex 1.196b 43 .280 
Therapy 4.204b 43 .046 
 
Table A13 This table contains the statistics showing the factor, error df, and significance for factor, 
sex, and therapy for latency movements that show significance in both Factor (before vs after) and 
between-Therapy (OBVAT vs Sham).  It also shows the t, df, and significance of the post hoc 
analysis done to determine whether OBVAT or sham therapy had significance before/after therapy. 
The tests with significant Factor data are highlighted in green. The tests with significant between-
therapy data are highlighted in yellow. Tests with significance seen in the post hoc analysis are 
highlighted orange. 
 
Latency 
 
 F Error df Sig  
 
FastCon 212 
Factor 6.800b 40 0.0127  t df sig 
Sex .037b 40 0.8492 Active -3.969 21 0.001 
Therapy 5.462b 40 0.0245 Placebo -0.611 20 0.548 
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Table A14 This table contains the statistics showing the factor, error df, and significance for factor, 
sex, and therapy for peak velocity movements that show significance in both Factor (before vs 
after) and between-Therapy (OBVAT vs Sham). It also shows the t, df, and significance of the post 
hoc analysis done to determine whether OBVAT or sham therapy had significance before/after 
therapy. The tests with significant Factor data are highlighted in green. The tests with significant 
between-therapy data are highlighted in yellow. Tests with significance seen in the post hoc 
analysis are highlighted orange. 
 
 
Peak Velocity 
 
 F Error df Sig  
 
Con 26 
Factor 6.278b 41 0.0163  t df sig 
Sex 1.197b 41 0.2803 Active -5.368 21 .000 
Therapy 6.386b 41 0.0155 Placebo -0.29 22 0.774 
Con 28 
Factor 8.910b 42 0.0047  t df sig 
Sex .442b 42 0.5099 Active -4.204 21 .000 
Therapy 13.090b 42 0.0008 Placebo -0.956 21 0.35 
Con 610 
Factor 4.094b 41 0.0496  t df sig 
Sex .091b 41 0.7646 Active -3.472 21 0.002 
Therapy 4.438b 41 0.0413 Placebo -0.356 21 0.726 
Con 812 
Factor 6.755b 43 0.0128  t df sig 
Sex .000b 43 0.9909 Active -4.443 22 .000 
Therapy 7.111b 43 0.0108 Placebo -0.273 22 0.788 
DS Con 26 
Factor 7.565b 39 0.0090  t df sig 
Sex .108b 39 0.7447 Active -3.327 21 .003 
Therapy 5.000b 39 0.0311 Placebo -0.663 19 0.515 
DS Con 28 
Factor 4.691b 40 0.0363  t df sig 
Sex .232b 40 0.6327 Active -2.931 21 0.008 
Therapy 4.910b 40 0.0325 Placebo -0.863 20 0.398 
DS Con 48 
Factor 5.038b 40 0.0304  t df sig 
Sex .077b 40 0.7825 Active -4.163 21 .000 
Therapy 9.872b 40 0.0032 Placebo 0.458 20 0.652 
FastCon 212 
Factor 8.753b 44 0.0050  t df sig 
Sex .263b 44 0.6108 Active -3.901 22 0.001 
Therapy 10.450b 44 0.0023 Placebo 0.156 23 0.878 
SlowCon 28 
Factor 8.124b 40 0.0069  t df sig 
Sex .506b 40 0.4812 Active -4.423 21 .000 
Therapy 5.521b 40 0.0238 Placebo -1.165 20 0.258 
SlowCon 
612 
Factor 4.726b 42 0.0354  t df sig 
Sex .363b 42 0.5500 Active -4.738 21 .000 
Therapy 14.408b 42 0.0005 Placebo 1.175 22 0.253 
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Table A15 This table contains the statistics showing the factor, error df, and significance for factor, 
sex, and therapy for final amplitude movements that show significance in both Factor (before vs 
after) and between-Therapy (OBVAT vs Sham). It also shows the t, df, and significance of the post 
hoc analysis done to determine whether OBVAT or sham therapy had significance before/after 
therapy. The tests with significant Factor data are highlighted in green. The tests with significant 
between-therapy data are highlighted in yellow. Tests with significance seen in the post hoc 
analysis are highlighted orange. 
 
 
Final Amplitude 
 
 F Error df Sig  
FastCon 212 
Factor 6.800b 40 0.0127  t df sig 
Sex .037b 40 0.8492 Active -3.969 21 0.001 
Therapy 5.462b 40 0.0245 Placebo -0.611 20 0.548 
FastDiv 122 
Factor 13.310b 40 0.0008  t df sig 
Sex .056b 40 0.8143 Active 4.417 20 .000 
Therapy 6.678b 40 0.0135 Placebo 1.667 21 0.11 
SlowDiv 82 
Factor 6.360b 44 0.0154  t df sig 
Sex .720b 44 0.4007 Active 3.111 22 0.005 
Therapy 5.144b 44 0.0283 Placebo 0.07 23 0.945 
L2M10 
Factor 4.176b 40 0.0476  t df sig 
Sex .031b 40 0.8605 Active 4.569 21 .000 
Therapy 8.542b 40 0.0057 Placebo -0.302 20 0.766 
M2L10 
Factor 4.731b 41 0.0354  t df sig 
Sex 1.295b 41 0.2618 Active -3.352 21 0.003 
Therapy 6.413b 41 0.0153 Placebo 0.543 21 0.593 
M2R10 
Factor 5.191b 44 0.0276  t df sig 
Sex .388b 44 0.5366 Active 4.682 24 .000 
Therapy 11.945b 44 0.0012 Placebo -0.777 21 0.446 
R2M10 
Factor 5.514b 41 0.0238  t df sig 
Sex .327b 41 0.5704 Active -3.319 21 0.003 
Therapy 4.760b 41 0.0349 Placebo -0.109 21 0.914 
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Table A16 This table contains the statistics showing the factor, error df, and significance for factor, 
sex, and therapy for main sequence ratio movements that show significance in both Factor (before 
vs after) and between-Therapy (OBVAT vs Sham). It also shows the t, df, and significance of the 
post hoc analysis done to determine whether OBVAT or sham therapy had significance before/after 
therapy.  The tests with significant Factor data are highlighted in green. The tests with significant 
between-therapy data are highlighted in yellow. Tests with significance seen in the post hoc 
analysis are highlighted orange. 
 
 
Main Sequence Ratio 
 
 F Error df Sig  
Con 48 
Factor 4.291b 45 0.0441  t df sig 
Sex 1.740b 45 0.1938 Active -3.485 23 0.002 
Therapy 7.270b 45 0.0098 Placebo 0.836 23 0.412 
DS Div 84 
Factor 9.879b 40.000 0.0031  t df sig 
Sex 3.324b 40.000 0.0757 Active -0.502 20 0.621 
Therapy 5.799b 40.000 0.0207 Placebo -2.643 21 0.015 
SlowCon 
612 
Factor 18.788b 39.000 0.0001  t df sig 
Sex 3.271b 39.000 0.0782 Active -1.672 21 0.109 
Therapy 4.280b 39.000 0.0452 Placebo -3.731 19 0.001 
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APPENDIX B 
BEHAVIORAL PLOTS 
 
 
Figure B1 This figure shows comparison plots of subject step movements before and after 
therapy for both active and placebo therapies.  
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Figure B2 This figure shows comparison plots of subject step ramp movements before and after 
therapy for both active and placebo therapies.  
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Figure B3 This figure shows comparison plots of subject disappearing step movements before 
and after therapy for both active and placebo therapies.  
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Figure B4 This figure shows comparison plots of subject saccade movements before and after 
therapy for both active and placebo therapies. The green trace is the average of all individual 
movements. 
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Figure B5 This figure shows ensemble plots of subject convergence movements before and after 
therapy for both active (right) and placebo (left) therapies. The green trace is the average of all 
individual movements. 
 
Figure B6 This figure shows ensemble plots of subject convergence disappearing step 
movements before and after therapy for both active (right) and placebo (left) therapies. The green 
trace is the average of all individual movements. 
Placebo        Active 
Placebo      Active 
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Figure B7 This figure shows ensemble plots of subject convergence stepramps movements 
before and after therapy for both active (right) and placebo (left) therapies. The green trace is the 
average of all individual movements. 
 
 
Figure B8 This figure shows ensemble plots of subject saccade movements before and after 
therapy for both active (right) and placebo (left) therapies. The green trace is the average of all 
individual movements. 
Placebo        Active 
Placebo        Active 
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Figure B9 This figure shows ensemble plots of subject divergence movements before and after 
therapy for both active (right) and placebo (left) therapies. The green trace is the average of all 
individual movements. 
 
Figure B10 This figure shows ensemble plots of subject divergence disappearing step movements 
before and after therapy for both active (right) and placebo (left) therapies. The green trace is the 
average of all individual movements. 
Placebo        Active 
Placebo        Active 
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Figure B11 This figure shows ensemble plots of subject divergence stepramps movements before 
and after therapy for both active (right) and placebo (left) therapies. The green trace is the 
average of all individual movements. 
 
Figure B12 This figure shows ensemble plots of subject saccade movements before and after 
therapy for both active (right) and placebo (left) therapies. The green trace is the average of all 
individual movements. 
Placebo        Active 
Placebo        Active 
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APPENDIX C 
BAR PLOTS OF PARAMETERS 
 
Figure C1 This figure shows the means and standard deviations for convergence and divergence 
movements for both the active and placebo therapies. 
 
Figure C2 This figure shows the means and standard deviations for disappearing step 
convergence and disappearing step divergence movements for both the active and placebo 
therapies. 
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Figure C3 This figure shows the means and standard deviations for stepramp convergence and 
stepramp divergence movements for both the active and placebo therapies. 
 
Figure C4 This figure shows the means and standard deviations for saccadic movements for both 
the active and placebo therapies. 
** 
*         P<.05 
**       P<.01 
 76 
 
Figure C5 This figure shows the means and standard deviations for convergence and divergence 
movements for both the active and placebo therapies. 
 
Figure C6 This figure shows the means and standard deviations for disappearing step 
convergence and disappearing step divergence movements for both the active and placebo 
therapies. 
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Figure C7 This figure shows the means and standard deviations for stepramp convergence and 
stepramp divergence movements for both the active and placebo therapies. 
 
Figure C8 This figure shows the means and standard deviations for saccadic movements for both 
the active and placebo therapies. 
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Figure C9 This figure shows the means and standard deviations for convergence and divergence 
movements for both the active and placebo therapies. 
 
Figure C10 This figure shows the means and standard deviations for disappearing step 
convergence and disappearing step divergence movements for both the active and placebo 
therapies. 
** 
** 
** 
** 
*         P<.05 
**       P<.01 
** ** 
** 
*         P<.05 
**       P<.01 
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Figure C11 This figure shows the means and standard deviations for stepramp convergence and 
stepramp divergence movements for both the active and placebo therapies. 
 
Figure C12 This figure shows the means and standard deviations for saccadic movements for 
both the active and placebo therapies. 
** ** 
** 
*         P<.05 
**       P<.01 
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Figure C13 This figure shows the means and standard deviations for convergence and divergence 
movements for both the active and placebo therapies. 
 
Figure C14 This figure shows the means and standard deviations for disappearing step 
convergence and disappearing step divergence movements for both the active and placebo 
therapies. 
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Figure C15 This figure shows the means and standard deviations for stepramp convergence and 
stepramp divergence movements for both the active and placebo therapies. 
 
Figure C16 This figure shows the means and standard deviations for saccadic movements for 
both the active and placebo therapies. 
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Figure C17 This figure shows the means and standard deviations for convergence and divergence 
movements for both the active and placebo therapies. 
 
Figure C18 This figure shows the means and standard deviations for stepramp convergence and 
stepramp divergence movements for both the active and placebo therapies. 
** 
** 
** 
*         P<.05 
**       P<.01 
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Figure C19 This figure shows the means and standard deviations for saccadic movements for 
both the active and placebo therapies. 
 
Figure C20 This figure shows the means and standard deviations for convergence and divergence 
movements for both the active and placebo therapies. 
** ** ** 
** 
*         P<.05 
**       P<.01 
** 
*         P<.05 
**       P<.01 
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Figure C21 This figure shows the means and standard deviations for disappearing step 
convergence and disappearing step divergence movements for both the active and placebo 
therapies. 
 
Figure C22 This figure shows the means and standard deviations for stepramp convergence and 
stepramp divergence movements for both the active and placebo therapies. 
** 
*         P<.05 
**       P<.01 
** 
*         P<.05 
**       P<.01 
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Figure C23 This figure shows the means and standard deviations for saccadic movements for 
both the active and placebo therapies. 
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APPENDIX D 
CONVERGENCE INSUFFICIENCY SYMPTOM SURVEY 
 
 
Figure D1 Convergence Insufficiency Symptom Survey (CISS) used to determine subject 
use in study. The survey detects CI via the subject’s symptoms. Scores below 10 indicate 
a binocularly normal subject. 
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